3SBio Sees Strong Growth In Q1 Driven By Oncology Product EPIAO
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Biotech company 3SBio saw revenues increase 23.7 percent in the first quarter of 2009, driven by the company's leading recombinant human erythropoietin injection EPIAO, the only approved EPO drug in China
You may also be interested in...
Reeling From Lehman Bros-linked Loss, China’s 3SBio Aims To Bioengineer Its Own Recovery
BEIJING - Stung by a loss of nearly $3 million in late 2008 tied to the U.S. financial meltdown, leading Chinese biopharmaceutical outfit 3SBio is laying the drug development groundwork for a profit rebound this year and next
3SBio Files For Approval For Interleukin-2 NuLeusin
SHANGHAI - 3SBio filed an application for the approval of NuLeusin with China's State FDA Nov. 10, hoping to make it the first product of its kind on the Chinese market, the Shenyang-based company announced
3SBio And AMAG Ink Deal To Develop Ferumoxytol In China
SHANGHAI - China's 3SBio Pharmaceutical and U.S.-based AMAG Pharmaceuticals have entered into a strategic partnership to develop and commercialize AMAG's nanoparticle agent Ferumoxytol in China, the two companies announced May 27